What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism University of Manitoba Principal Investigator Diabetes Research Group John Buhler Research Centre Winnipeg, Manitoba, Canada